Let’s talk fashion and evidence.

In the world of style, few revolutions were as transformative as the rise of ready-to-wear (prêt-à-porter). It made high fashion accessible, inclusive, and wearable, off the runway and into real life. Clinical research is having a similar moment.

If randomized controlled trials (RCTs) are the haute couture of science, tailored under perfect conditions for ideal subjects, then real-world evidence (RWE) is the bold, everyday style that meets people where they are. Think denim jacket, white tee, and a clean pair of Jordans… real, relevant, and built for the streets we actually walk. RWE is reshaping how we generate, interpret, and apply data in oncology and making evidence more inclusive along the way.

RCTs vs. RWE: From Runway to Real Life

Feature	RCTs (Runway Couture)	RWE (Everyday Style)
Setting	Controlled trial sites	Real-world clinics, hospitals, communities
Population	Carefully selected	Broad, diverse, inclusive
Purpose	Prove efficacy	Understand effectiveness
Style Match	Designer gown on the runway	Denim jacket, white tee, and a clean pair of Jordans in real life

RCTs are powerful. They help us prove that a treatment works under ideal conditions. They are the scientific gold standard when it comes to establishing cause and effect. Without them, we wouldn’t have many of the treatments we rely on today.

But in oncology, where complexity is the norm, we need more than ideal. We need relevant. We need real.

That is where RWE comes in, not as a replacement, but as a necessary complement that helps us understand how those treatments perform across the diverse realities of patients’ lives.

Why RWE Is Rising in Oncology

Oncology is in overdrive. Precision therapies, biomarker-driven decisions, and rapidly shifting standards of care all demand timely, relevant evidence. Here’s how RWE meets the moment:

• Speed matters: We can’t always wait for years of trial results, especially for aggressive or rare cancers.
  
• Precision demands context: Biomarkers tell us who may benefit. RWE shows us how treatments perform in real life.
  
• Equity is non-negotiable: RWE includes patients historically excluded from trials, including older adults, communities of color, and those with co-morbidities or access barriers.
  

Regulators and Payers Are Taking Note

And it’s not just researchers paying attention.

Regulators like the Food and Drug Administration (FDA) are accepting RWE to support oncology label expansions and have issued guidance on using RWE throughout the drug lifecycle.

Health insurers and payment decision-makers are also following suit.

The Centers for Medicare and Medicaid Services (CMS) and commercial health insurance companies are incorporating RWE into coverage decisions, especially for high-cost oncology drugs. Under the Inflation Reduction Act, CMS is now using RWE in Medicare drug price negotiations.

Globally, health technology assessment (HTA) bodies like NICE in the UK and HAS in France are also relying on RWE to inform pricing, reimbursement, and access decisions, especially when RCT data are sparse or unrepresentative.

Fashioning Evidence That Fits

Imagine choosing an outfit based solely on how it fit a model in Milan, who looks nothing like you, lives in a different climate, and has a completely different lifestyle.

That’s what we do when we solely rely on RCTs for evidence.

RWE allows us to ask:

• Does this treatment work the same for older adults with other health issues?
  
• Do side effects vary across race, gender, or income?
  
• Does access to care, or lack of it, change the outcome?
  

These aren’t niche questions. They are central to delivering high-quality, equitable oncology care.

When we pair the rigor of RCTs with the relevance of RWE, we get a more complete picture. One that reflects both scientific precision and lived experience.

Why RWE Is the New Black

Because it’s timeless. Versatile. And essential.

Just like a black blazer or a go-to pair of Jordans, RWE is a staple. It doesn’t replace RCTs, but it completes the look. It fills the evidence gaps, grounds science in everyday realities, and makes data work for everyone.

Final Thought: Data Shouldn’t Be a Runway Fantasy

In fashion, what we wear every day needs to fit our lives, not just the runway.

In science, the evidence we use should do the same.

RCTs help us test what’s possible. RWE helps us understand what’s practical.

RWE is making data more inclusive, more timely, and more useful, one dataset at a time.

Because in the end, the goal isn’t just scientific elegance. It’s practical impact.

Join the Movement

At Evidence in Style^TM science meets storytelling and cancer education gets a bold new look.

From fashion to film, real-world data to real life, we’re here to make complex cancer concepts accessible, memorable, and empowering.

Whether you’re a patient, a caregiver, a researcher, or just curious about cancer and how evidence actually works, this space is for you.

✨ Subscribe to stay up to date on the latest EIS Note drop!